Physician profile
Florence Comite
NPI 1790998540
$4,052.49
in general payments reported to CMS, 2019-2025
25 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $677 · 2021: $1,065 · 2022: $679 · 2023: $427 · 2024: $265 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.12 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $774.66 | 2021 | |
| Amgen INC. | $553.16 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $480.05 | 2019-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.39 | 2020-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $323.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $298.07 | 2019-2025 | Farxiga |
| Baxter Healthcare | $278.72 | 2022 | |
| Medical Graphics Corporation | $175.85 | 2020 | |
| Antares Pharma, INC. | $136.18 | 2019-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $136.02 | 2024-2025 | |
| Abbott Laboratories | $101.90 | 2019 | |
| Amarin Pharma, INC. | $96.94 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $62.79 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $44.62 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $30.47 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $29.56 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $27.21 | 2019 | |
| Dexcom, INC. | $25.89 | 2023 | Dexcom G6 Transmitter |
| Halozyme INC | $21.26 | 2023 | |
| Abbvie INC. | $21.06 | 2023 | Linzess |
| Horizon Therapeutics Plc | $20.83 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.90 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.95 | 2025 | Azmiro |
| Metuchen Pharmaceuticals | $15.12 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Comite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.